CN106029082A - 用于减轻外周炎症和疼痛的含有姜黄(Curcuma longa)和狭叶松果菊提取物的组合物 - Google Patents

用于减轻外周炎症和疼痛的含有姜黄(Curcuma longa)和狭叶松果菊提取物的组合物 Download PDF

Info

Publication number
CN106029082A
CN106029082A CN201580009045.8A CN201580009045A CN106029082A CN 106029082 A CN106029082 A CN 106029082A CN 201580009045 A CN201580009045 A CN 201580009045A CN 106029082 A CN106029082 A CN 106029082A
Authority
CN
China
Prior art keywords
extract
compositions
curcumin
echinacea
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580009045.8A
Other languages
English (en)
Inventor
E·邦巴尔代利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN106029082A publication Critical patent/CN106029082A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/758—Zanthoxylum, e.g. pricklyash
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及组合物，其含有作为其仅有活性成分的姜黄属物种提取物(任选地作为与磷脂的复合物形式的姜黄素)，以及选自松果菊属物种提取物或花椒属物种亲脂提取物的提取物，所述组合物可用于外周疼痛，以及表面和深度炎症与疼痛病症的局部和全身治疗。根据本发明的组合物在不能耐受NSAIDs或甾体类的长期治疗的患者的骨关节炎和类风湿性关节炎的治疗中是特别有效的。

Description

用于减轻外周炎症和疼痛的含有姜黄(Curcuma longa)和狭 叶松果菊提取物的组合物
发明概述
本发明涉及组合物，其含有作为其仅有活性成分的姜黄属物种(Curcuma spp)提取物(任选地作为与磷脂的复合物形式的姜黄素)，以及选自松果菊属物种(Echinaceaspp)提取物或花椒属物种(Zanthoxylum spp)亲脂提取物的提取物，所述组合物可用于外周疼痛以及表面和深度炎症与疼痛病症的局部和全身治疗。根据本发明的组合物在不能耐受NSAIDs或甾体类的长期治疗的患者的骨关节炎和类风湿性关节炎(rheumatoidarthritis)的治疗中，是特别有效的。
现有技术状况
骨关节炎是老年人身体障碍的主要原因之一。除降低全世界数百万个体的生活质量之外，其还为家庭和社会带来经济损失，因为与护理相关的花费是非常高的。
骨关节炎的常规治疗涉及用镇痛药的对症治疗，以及用非甾体抗炎药物的治疗，所述治疗已知产生严重副作用，该副作用经常致使治疗中断。类似的考虑也适用于类风湿性关节炎。由于所述原因，研究还已普遍关注于植物治疗药物和天然植物疗法。
由于其异丁酰胺含量，松果菊属物种的亲脂提取物和酒精提取物具有局部和全身抗炎活性，异丁酰胺类是CB1和CB2大麻素受体和辣椒素(vanilloid)受体TRPV1的配体。由于其高异丁酰胺含量，EP 0464298中所述的狭叶松果菊(Echinacea angustifolia)亲脂提取物在该方面是特别有效的。
远古以来，姜黄(姜黄属(Curcuma))的根和根茎已在印度用作香料，并且今天，其还在许多工业化国家使用。其活性成分是姜黄素，该黄色化合物构成咖喱和其他传统印度菜肴的主要成分。传统药物中所述的用途包括消化不良、肠胃气胀和腹泻的治疗，并且尤其是长期治疗后的炎症病症和关节疼痛的治疗。已经通过体外生物化学试验或药理学确证了许多所述传统用途。
现在，从生物化学角度来看，姜黄素是最常研究的分子之一，并且在近些年，除了难确定科学价值的大量出版物，还根据现代临床药理学方案，已经进行对照双盲临床试验。初步的临床试验已显示该分子的低生物利用度，其在肠道pH下是不稳定的(pH 7下的半衰期<10min)，以及显示其低的口服吸收，这限制了许多体外试验中指示的用途。施用12g化合物后，报道血浆浓度为50ng，还测量了次级代谢产物、葡糖醛酸苷类和硫酸酯类。
如同许多多酚类，姜黄素难溶于水和脂肪。因此，本申请人设计了专利WO2007101551，其描述姜黄素与磷脂的复合，以提高姜黄素的生物利用度。磷脂-复合形式的姜黄素提供提高的全身和局部吸收，这使得其可被施用至人类。
对患骨关节炎的患者进行的临床试验已显示用磷脂-复合的姜黄素长期治疗(Belcaro等人，Alternative Medicine Review，4，338,2010)产生有益的结果，但由于疼痛降低的水平低，其仍是不充足的结果，这迫使患者服用NSAIDs。
然而，显著的改善仅在8个月的治疗后获得，并且许多患者必须服用NSAIDs或其他镇痛药，已减轻疼痛。
发明描述
现在，令人吃惊地发现含有作为仅有活性成分的姜黄属物种提取物以及选自松果菊属物种提取物或花椒属物种亲脂提取物的提取物的组合物具有潜在的镇痛和抗炎活性，所述活性比将所述提取物单独使用时发现的活性更大。
用含有磷脂-复合姜黄素和狭叶松果菊亲脂提取物的组合物，已观察到特别有益的结果。
通过用其他含有高异丁酰胺含量的植物提取物尤其是花椒属物种亲脂提取物代替松果菊属物种提取物，也已得到良好的结果。
因此，本发明的目标是基本上由与可接受的赋形剂混合的姜黄属物种提取物或姜黄素以及选自狭叶松果菊提取物或者花椒(Zanthoxylum bungeanum)亲脂提取物的提取物构成的组合物。
本发明特别涉及基本上由与可接受的赋形剂混合的姜黄属物种提取物或姜黄素以及选自狭叶松果菊提取物或者花椒亲脂提取物的提取物构成的组合物。
可将根据本发明的组合物口服或局部施用。
根据一优选方面，每口服剂量单位，口服施用的组合物将含有100-1000mg的量的磷脂-复合的姜黄素，以及1-200mg的量的松果菊属提取物，或者替代的5-25mg的量的花椒属物种亲脂提取物。根据一特别优选方面，每口服剂量单位，口服施用的组合物将含有500mg磷脂-复合的姜黄素，以及5mg松果菊属提取物或者替代的10mg花椒属物种亲脂提取物。
根据一优选方面，局部施用的组合物将含有0.1-0.5重量％的量的磷脂-复合的姜黄素，以及0.05-0.5重量％的量的松果菊属提取物或者替代的0.1-1重量％的量的花椒属物种亲脂提取物。根据一特别优选方面，局部施用的组合物将含有0.2重量％磷脂-复合的姜黄素，以及0.2重量％的松果菊属提取物或者替代的0.5重量％的花椒属物种亲脂提取物。
可将根据本发明的组合物用于治疗所有种类的外周疼痛，从糖尿病神经病变至各种起源的关节和肌肉疼痛。特别重要的是，根据本发明的组合物在胃肠道中不引起副作用，从而允许有胃部问题而不能耐受NSAIDs的患者使用。
可通过用醇、酮或脂肪族醚或者优选地根据EP464298用超临界条件下的二氧化碳提取根部或根茎，得到松果菊属的亲脂提取物。
也含有药理活性量的异丁酰胺的松果菊属酒精提取物已证实是有效的，前提是至少将1mg最小剂量的异丁胺复合物施用至患者。对于平均体重70Kg，活性临床剂量是0.5mg-10mg，优选5mg。
花椒属物种亲脂提取物可根据WO 00/02570制备。
然而，根据本发明的组合物几乎立即缓解患者症状，而不需要使用其他药物。患有胃食管反流和溃疡前阶段的患者也能服用根据本发明的组合物。
药理学试验
1.大鼠甩尾试验
将根据本发明组合物的镇痛活性(磷脂-复合的姜黄素和松果菊属提取物的组合)与单独向大鼠施用的个体成分的活性进行比较。结果显示根据本发明组合物的两种组分间有清楚的协同作用，如下表1中所示。
用大鼠甩尾试验评价镇痛活性。治疗前，对动物进行3次基本测量，以保证他们适合于相关的操作和设备。所用的参数是15V辐射热和15-秒断开(以防止对动物的不可逆伤害)，评价甩尾。用0.1ml实施例4中所述的组合物软膏，距离尾底部5cm，治疗动物。施用后15和30min，测量镇痛作用。
用相同试验模型，用含有与实施例4中所述组合物相同量的活性成分之一的两种单独制剂，评价组合物的两种个体成分。将对照动物用0.1ml用于溶解两种成分的油(载体)治疗。
表1
2.人中的镇痛活性
将40患有持续痛膝盖骨病的患者随机分组，并用实施例1一天两片治疗，上午一片，晚上一片；或者用安慰剂(仅由载体构成)治疗；或者用与实施例1中所述制剂的相同浓度添加到安慰制剂中的个体成分治疗。
根据0-10分的国际模拟疼痛测量表，将效力进行评分，10分表明最大疼痛，且0分表明疼痛消失。在片剂施用后的第二天，上午治疗后60和120分钟，评价效果。
下表2中列出结果。
表2
3.对骨关节炎的作用
表3显示用根据本发明的组合物治疗至多3个月后，在招募的患者的骨关节炎的总体作用得到的结果，对于效力的选择和评价，根据卡诺夫斯基量表(Karnofsky Scale)(J.Clin.Oncology 1984；2：187-193)。
在设定至3Km/h和10％倾角的跑台上，通过测量没有疼痛的条件下移行的距离，并用不同的疼痛程度，进行评价。将患有膝盖骨关节炎的80名患者分成两组。随机分组后，将一组用安慰剂治疗，并且另一组用实施例1中所述的组合物治疗。治疗期间，用WOMAC指标，每周评价疼痛，并且每月评价体液参数，所述参数构成炎症参数指标。(表4).
表3.跑台上移行距离的结果
Xx由于伦理原因离开试验的患者或者用其他药物治疗的患者。
表4.一些炎症标记物的评价
已证实凝胶剂、乳膏剂和软膏剂形式的药物组合物特别用于外周疼痛以及表面和深度炎症和疼痛病症的局部治疗。所述组合可在溶解其的油中直接施用至皮肤，或者可被引入适合施用的乳膏剂或软膏剂中。可以每天1-3次向受疼痛病患影响的身体部位施用0.5-5g剂量的局部制剂，完成治疗。
根据另一方面，可将根据本发明的组合物与具有有用的或互补活性的其他物质一起施用。
可以根据常规技术例如“Remington’s Pharmaceutical Handbook”，MackPublishing Co.，N.Y.，USA中所述的那些，配制本发明的组合物。
下面的实施例进一步解释本发明。
实施例1–含有磷脂-复合的姜黄素和松果菊亲脂提取物的片剂
实施例2–软明胶胶囊
磷脂-复合的姜黄素 300.00mg
用CO2提取的狭叶松果菊 5.00mg
标准化至25％异丁酰胺
亚麻籽油 至700mg
实施例3-含有磷脂-复合的姜黄素和松果菊酒精提取物的片剂
实施例4-含有磷脂-复合的姜黄素和狭叶松果菊亲脂提取物的软膏剂

Claims (11)

1.组合物，其基本上由与可接受的赋形剂混合的姜黄属物种提取物或姜黄素以及选自狭叶松果菊提取物或者花椒亲脂提取物的提取物构成。
2.根据权利要求1的组合物，其中姜黄素是与磷脂复合的。
3.根据权利要求1的组合物，其中通过用超临界二氧化碳提取，制备狭叶松果菊提取物和花椒提取物。
4.根据上述权利要求的组合物，其用于口服施用。
5.根据权利要求4的组合物，其每口服剂量单位含有作为仅有的活性成分的100-1000mg的量的与磷脂复合的姜黄素，以及1-20mg的量的松果菊属提取物或者替代的5-25mg的量的花椒属物种亲脂提取物。
6.根据权利要求5所述的组合物，其每口服单位剂量含有作为仅有的活性成分的500mg与磷脂复合的姜黄素，以及5mg松果菊属提取物或者替代的10mg花椒属物种亲脂提取物。
7.根据权利要求1-3所述的组合物，其用于局部施用。
8.根据权利要求7所述的组合物，其含有0.1％-0.5％w/w的量的与磷脂复合的姜黄素，以及0.05％-0.5％w/w的量的松果菊属提取物，或者0.1-1％w/w的量的花椒属物种亲脂提取物。
9.根据权利要求8所述的组合物，其含有0.2％w/w与磷脂复合的姜黄素，以及0.2％w/w的松果菊属提取物，或者替代的0.5％w/w的花椒属物种亲脂提取物。
10.根据权利要求1-9所述的组合物，其用于治疗外周疼痛、关节和肌肉疼痛、炎症性以及表面和深度疼痛病症。
11.根据权利要求10所述的组合物，其用于治疗骨关节炎和类风湿性关节炎。
CN201580009045.8A 2014-02-20 2015-02-18 用于减轻外周炎症和疼痛的含有姜黄(Curcuma longa)和狭叶松果菊提取物的组合物 Pending CN106029082A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2014A000251 2014-02-20
ITMI20140251 2014-02-20
PCT/EP2015/053399 WO2015124616A1 (en) 2014-02-20 2015-02-18 Compositions containing extracts of curcuma longa and echinacea angustifolia which are useful to reduce peripheral inflammation and pain

Publications (1)

Publication Number Publication Date
CN106029082A true CN106029082A (zh) 2016-10-12

Family

ID=50336467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580009045.8A Pending CN106029082A (zh) 2014-02-20 2015-02-18 用于减轻外周炎症和疼痛的含有姜黄(Curcuma longa)和狭叶松果菊提取物的组合物

Country Status (19)

Country Link
US (1) US10286028B2 (zh)
EP (1) EP3107555B1 (zh)
JP (1) JP6510544B2 (zh)
KR (1) KR102350519B1 (zh)
CN (1) CN106029082A (zh)
AU (1) AU2015220913B2 (zh)
BR (1) BR112016018973B1 (zh)
CA (1) CA2939976C (zh)
DK (1) DK3107555T3 (zh)
ES (1) ES2804324T3 (zh)
HU (1) HUE051696T2 (zh)
IL (1) IL247314B (zh)
MX (1) MX2016010722A (zh)
PL (1) PL3107555T3 (zh)
PT (1) PT3107555T (zh)
RU (1) RU2677894C2 (zh)
SG (1) SG11201606831PA (zh)
SI (1) SI3107555T1 (zh)
WO (1) WO2015124616A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132654A (zh) * 2017-09-29 2020-05-08 Ucl有限公司 具有预防和缓解头皮炎症及预防脱发的效果的化妆品组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150214A1 (en) * 2015-10-01 2017-04-05 INDENA S.p.A. Compositions containing extracts of curcuma spp and zingiber officinale which are useful to reduce peripheral inflammation and pain
AU2016373576B2 (en) * 2015-12-16 2022-06-02 Vivek Anand PARACHUR Tri-molecular complex of natural compounds
ITUB20161030A1 (it) 2016-02-24 2017-08-24 Indena Spa Composizioni utili nella prevenzione e/o nel trattamento dell’infiammazione e del dolore
US10744174B1 (en) * 2016-03-16 2020-08-18 Robert Alonso Composition(s) and method(s) for topically treating pain
ITUA20164757A1 (it) 2016-06-29 2017-12-29 Indena Spa Composizioni utili nella prevenzione e/o nel trattamento dell’infiammazione e del dolore osteoarticolare e del danno cartilagineo
JP6987528B2 (ja) * 2017-05-12 2022-01-05 小林製薬株式会社 クルクミノイド含有錠剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464298A1 (en) * 1990-07-05 1992-01-08 INDENA S.p.A. Echinacea extracts, a process for the preparation thereof and formulations containing them
CN1308541A (zh) * 1998-07-07 2001-08-15 因迪纳有限公司 花椒的提取物,含有它们的药物和化妆品制剂
US6440448B1 (en) * 1998-03-16 2002-08-27 Joseph Intelisano Food supplement/herbal composition for health enhancement
EP1837030A1 (en) * 2006-03-09 2007-09-26 INDENA S.p.A. Phospholipid complexes of curcumin having improved bioavailability
EP2014295A2 (en) * 2007-06-04 2009-01-14 Velleja Research SRL Topical compositions for the prevention and treatment of inflammatory and/or infective conditions of the genital area
CN101607068A (zh) * 2009-07-15 2009-12-23 中国人民解放军第四军医大学 一种治疗肝癌中药前体脂质体注射剂及其制备工艺
CN103096907A (zh) * 2010-07-26 2013-05-08 因德纳有限公司 可用于减轻炎症和外周疼痛的含有狭叶紫锥菊和姜的提取物的制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5032003B2 (ja) 2005-06-15 2012-09-26 株式会社琉球バイオリソース開発 口腔粘膜用の鎮痛・抗炎症トローチ剤
KR20090047637A (ko) 2007-11-08 2009-05-13 재단법인서울대학교산학협력재단 커큐민 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 통증 예방 및 치료용 조성물

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464298A1 (en) * 1990-07-05 1992-01-08 INDENA S.p.A. Echinacea extracts, a process for the preparation thereof and formulations containing them
ATE123947T1 (de) * 1990-07-05 1995-07-15 Indena Spa Echinacea-extrakte, verfahren zur herstellung und zubereitungen, die sie enthalten.
ES2075187T3 (es) * 1990-07-05 1995-10-01 Indena Spa Extractos de equinaceas, un procedimiento para su preparacion y formulaciones que los contienen.
US6440448B1 (en) * 1998-03-16 2002-08-27 Joseph Intelisano Food supplement/herbal composition for health enhancement
CN1308541A (zh) * 1998-07-07 2001-08-15 因迪纳有限公司 花椒的提取物,含有它们的药物和化妆品制剂
EP1837030A1 (en) * 2006-03-09 2007-09-26 INDENA S.p.A. Phospholipid complexes of curcumin having improved bioavailability
CN101400360A (zh) * 2006-03-09 2009-04-01 因德纳有限公司 具有改良生物利用度的姜黄素磷脂复合物
EP2014295A2 (en) * 2007-06-04 2009-01-14 Velleja Research SRL Topical compositions for the prevention and treatment of inflammatory and/or infective conditions of the genital area
CN101607068A (zh) * 2009-07-15 2009-12-23 中国人民解放军第四军医大学 一种治疗肝癌中药前体脂质体注射剂及其制备工艺
CN103096907A (zh) * 2010-07-26 2013-05-08 因德纳有限公司 可用于减轻炎症和外周疼痛的含有狭叶紫锥菊和姜的提取物的制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈进等: "微载体药物递送系统在姜黄素中的应用研究进展", 《中国现代应用药学》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132654A (zh) * 2017-09-29 2020-05-08 Ucl有限公司 具有预防和缓解头皮炎症及预防脱发的效果的化妆品组合物
CN111132654B (zh) * 2017-09-29 2022-11-04 Ucl有限公司 具有预防和缓解头皮炎症及预防脱发的效果的化妆品组合物

Also Published As

Publication number Publication date
RU2016133688A (ru) 2018-03-23
RU2677894C2 (ru) 2019-01-22
SI3107555T1 (sl) 2020-07-31
AU2015220913B2 (en) 2020-04-09
IL247314B (en) 2020-08-31
KR20160113631A (ko) 2016-09-30
JP6510544B2 (ja) 2019-05-08
KR102350519B1 (ko) 2022-01-14
HUE051696T2 (hu) 2021-03-29
EP3107555B1 (en) 2020-06-03
WO2015124616A1 (en) 2015-08-27
JP2017506241A (ja) 2017-03-02
ES2804324T3 (es) 2021-02-05
MX2016010722A (es) 2016-11-10
US10286028B2 (en) 2019-05-14
DK3107555T3 (da) 2020-08-10
PL3107555T3 (pl) 2020-11-30
SG11201606831PA (en) 2016-09-29
RU2016133688A3 (zh) 2018-08-30
EP3107555A1 (en) 2016-12-28
PT3107555T (pt) 2020-07-10
IL247314A0 (en) 2016-09-29
US20170049840A1 (en) 2017-02-23
AU2015220913A1 (en) 2016-09-01
CA2939976C (en) 2023-09-05
CA2939976A1 (en) 2015-08-27
BR112016018973B1 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
CN106029082A (zh) 用于减轻外周炎症和疼痛的含有姜黄(Curcuma longa)和狭叶松果菊提取物的组合物
CN103096907B (zh) 可用于减轻炎症和外周疼痛的含有狭叶紫锥菊和姜的提取物的制剂
CN112891399A (zh) 一种中药组合物及其用途和制备方法
ES2715373T3 (es) Composiciones terapéuticas y nutricionales para el tratamiento del síndrome del intestino irritable
CN103055281A (zh) 治疗鱼白头白嘴病的纯中药组合物及其制备方法
Sahebari et al. Inhibitory effect of aqueous extract of saffron (Crocus sativus L.) on adjuvant-induced arthritis in wistar rat
CN105497534A (zh) 一种防治电力职工电烧伤和火烧伤的防护品
CN104938805A (zh) 一种提高鸭产蛋率的添加剂
CN104758451A (zh) 一种治疗痛风的中药组合物
Martey et al. Advance in pre-clinical pharmacokinetics of paeoniflorin, a major monoterpene glucoside from the root of Paeonia lactiflora
CN103055152B (zh) 一种治疗鱼虾烂腮病的纯中药组合物及其制备方法
CN102068642A (zh) 治疗皮肤癣症的药物组合物及其制备方法和用途
CN104474469A (zh) 一种制备用于电灼伤膏状制剂的方法
CN108697751B (zh) 用于预防和/或治疗炎症和疼痛的组合物
Audrey et al. Evaluation of the anti-inflammatory activity of a gel based on Afzelia africana (fabaceae) leaves
EP3150214A1 (en) Compositions containing extracts of curcuma spp and zingiber officinale which are useful to reduce peripheral inflammation and pain
Ansari Abdullah et al. Arthritis (Waja ul Mafasil) in the light of Unani system of Medicine-A Review
CN105311370A (zh) 一种用于电烧伤的制剂及其制备工艺
Parulkar Geeta GOKSHURADI GUGGULU: A MEDICO REVIEW
Dalai et al. Evaluation of health promotion in elderly people through cyavanaprasa
CN105395773A (zh) 一种肩周炎配方的制作方法
CN107929665A (zh) 一种治疗骨质增生的中药组合物
Kumar et al. Laxative activity of spray dried aqueous seed extract of Linum usitatissimum(Linaceae)
CN104383448A (zh) 一种用于电灼伤的制剂
CN106267133A (zh) 一种治疗小儿腹泻的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1229731

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161012

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1229731

Country of ref document: HK